New 'gastric bypass pill' causes weight loss without side effects: study
Share this @internewscast.com

A new once-daily pill may raise the bar for weight loss meds.

Drugs like Ozempic and Mounjaro, which imitate the GLP-1 hormone that the body releases post-meal, can lead to notable weight reduction; however, they may also result in the loss of lean muscle mass as a side effect.

Developers of the experimental drug SYNT-101 assert that it replicates the outcomes of gastric bypass surgery while maintaining lean muscle mass more effectively than GLP-1 drugs.

“We are confident that SYNT-101 will offer a convenient, long-term oral solution and/or complement to systemic treatments like GLP-1 drugs,” stated Rahul Dhanda, CEO of Syntis Bio, the biopharmaceutical firm in Boston working on the development of the treatment.

SYNT-101 forms a synthetic film on the surface of the small intestine, shifting nutrient exposure to the lower intestine to promote a feeling of fullness. The lining is designed to work for up to 24 hours before it’s naturally cleared from the body.

In a new first-in-human study, seven women and two men between the ages of 24 and 53, who were not considered obese, took varying doses of SYNT-101 in liquid form.

Imaging confirmed that the coating formed across the upper small intestine, and tissue samples showed that SYNT-101 was safely expelled within 24 hours.

Further testing showed the participants had normal liver functioning and lower glucose absorption.

SYNT-101 promotes better energy balance, Dhanda said, lessening the body’s tendency to break down muscle tissue for fuel.

No serious side effects were reported.

Nausea is one of the most frequently reported side effects of GLP-1 drugs — and one of the major reasons why some users quit taking them.

Hair loss and skin pain are among the less common side effects. Blindness and behavioral changes can occur in very rare cases.

Weight loss was not tracked for this study, but the researchers said the results reflected reduced food consumption.

In rodent studies, SYNT-101 produced weight loss of 1% a week for six weeks while preserving 100% of lean muscle mass.

The new findings were presented this week at the European Congress on Obesity in Malaga, Spain.

“The millions of people living with obesity need novel treatment options that are safe, effective and avoid the high costs and severe side effects that often accompany available treatment options,” Dhanda said.

More research is needed to fully assess the drug’s efficacy and safety.

Syntis Bio plans to submit an Investigational New Drug (IND) application to the Food and Drug Administration later this year.

“We are eager to replicate these data in our upcoming Phase 1 clinical trial and further explore the ability of SYNT-101 to produce sustainable, safe, effective weight loss by reducing fat, preserving lean muscle and stimulating natural production of satiety hormones to prevent weight regain,” Dhanda said.

Share this @internewscast.com
You May Also Like
Football, family, humor, heart: Hulu's 'Chad Powers' has Glen Powell in sports spotlight at premiere at Pasadena's Rose Bowl

Glen Powell Steals the Show at Pasadena’s Rose Bowl Premiere with Hulu’s ‘Chad Powers’: A Blend of Football, Family, and Humor

Football and humor become intertwined in the new series “Chad Powers.” On…
Louisiana's governor asks for National Guard deployment to New Orleans and other cities

Governor of Louisiana Requests National Guard Assistance for New Orleans and Other Cities

NEW ORLEANS (AP) — The Republican governor of Louisiana has requested National…
Would SNAP, WIC be disrupted by a government shutdown?

Could a Government Shutdown Affect SNAP and WIC Programs?

(NEXSTAR) – In just a few hours, the U.S. government might face…
Woman charged with attempted murder in shooting at University of Alabama Arboretum

Woman Faces Attempted Murder Charge After Shooting at University of Alabama Arboretum

TUSCALOOSA, Ala. (WIAT) — A woman was charged with attempted murder following…
Blue city felon with violent history arrested in deadly train platform stabbing after parole release: report

Violent Ex-Felon Recently Released on Parole Arrested for Fatal Stabbing at Train Platform, Report Says

Police and a local news report indicate that a paroled felon with…
Texas woman with history of 5 marriages faces murder trial in husband's insulin death

Texas Woman with Five Previous Marriages Goes to Trial Over Husband’s Insulin-Related Death

Jury selection has begun in the high-profile murder trial of Sarah Hartsfield, the…
Reported threat at Jewish Congregation of Venice prompts large police response

Large Police Presence Responds to Reported Threat at Venice Jewish Congregation

The Jewish Congregation received phone calls threatening to “kill everyone,” according to…
ICE in Chicago: Federal agents surround South Shore apartment building as DHS requests military deployment to Illinois

Immigration Authorities in Chicago: Federal Agents Encircle South Shore Apartment as Homeland Security Seeks Military Assistance in Illinois

CHICAGO (WLS) — Questions remain after the announcement that the federal government…
ICE in Chicago protest: Broadview, Illinois leaders to address what they call 'unprovoked' use of chemical agents at ICE facility

Chicago ICE Protest: Broadview, Illinois Leaders Condemn Alleged ‘Unprovoked’ Use of Chemical Agents at ICE Facility

CHICAGO (WLS) — Officials from the village of Broadview are scheduled to…
ICE in Chicago: DHS requests military deployment to Illinois, Gov. JB Pritzker says during press conference today

DHS Requests Military Support in Illinois: Governor Pritzker Shares Updates on ICE Operations in Chicago

CHICAGO (WLS) — The Department of Homeland Security has requested the deployment…
Schools close in Bahamas as Tropical Storm Imelda approaches

Bahamas Schools Shut Down Due to Advancing Tropical Storm Imelda

Power outages were reported in certain regions, prompting authorities to close government…
James Comey's well-deserved indictment: Letters

James Comey Faces Indictment: A Look at the Details

The Issue: The indictment of former FBI Director James Comey for lying…